NCT06615557Phase 3Completed

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Study sponsor: VistaGen Therapeutics, Inc. · VTGN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-04-21Actual
Enrollment · participants238Actual
Source updated2026-11-04Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 236 participants (planned). After: 238 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Apr 2026. After: 21 Apr 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview